

Annex № 9
To Art. 33, par. 1, it.3 of Ordinance № 2 from
17.09.2003
And Regulation (EU) 596/2014 of the European
Parliament and of the Council
of 16 April 2014

INFORMATION ABOUT THE FACTS AND CIRCUMSTANCES OCCURRED
DURING THE NINE MONTHS OF 2020
OF "SOPHARMA" AD

- 1.1. No change in the persons controlling the Company.
- 1.2. (Annulled – State Gazette, issue 63 from 2016).
- 1.3. (Annulled – State Gazette, issue 63 from 2016).
- 1.4. (Annulled – State Gazette, issue 63 from 2016).
- 1.5. (Annulled – State Gazette, issue 63 from 2016).
- 1.6. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.
- 1.7. No acquisition, use or disposition of high-value assets.
- 1.8. No decision on conclusion, termination and cancellation of joint venture agreements.
- 1.9. (Annulled – State Gazette, issue 82 from 2007).
- 1.10. Change of the auditors of the company - At the Regular General Meeting of Shareholders of "SOPHARMA" AD, held on June 7, 2019, the auditing company "BAKER TILLY KLITOU AND PARTNERS" OOD, based in Sofia, Acad. "Ivan Evst. Geshov " 104, for a registered auditor for inspection and certification of the Annual Financial Statements of the Company.
- 1.11. (Annulled – State Gazette, issue 63 from 2016).
- 1.12. (Annulled – State Gazette, issue 63 from 2016).
- 1.13. (Annulled – State Gazette, issue 63 from 2016).
- 1.14. (Annulled – State Gazette, issue 63 from 2016).
- 1.15. (Annulled – State Gazette, issue 63 from 2016).
- 1.16. (Annulled – State Gazette, issue 63 from 2016).
- 1.17. (Annulled – State Gazette, issue 63 from 2016).
- 1.18. (Annulled – State Gazette, issue 63 from 2016).
- 1.19. (Annulled – State Gazette, issue 63 from 2016).
- 1.20. (Annulled – State Gazette, issue 63 from 2016).
- 1.21. (Annulled – State Gazette, issue 63 from 2016) No conclusion or performance of essential contracts, which do not relate to the ordinary business of the Company.
- 1.22. (Annulled – State Gazette, issue 63 from 2016).
- 1.23. (Annulled – State Gazette, issue 63 from 2016).
- 1.24. (Annulled – State Gazette, issue 63 from 2016).
- 1.25. (Annulled – State Gazette, issue 63 from 2016).
- 1.26. (Annulled – State Gazette, issue 63 from 2016).
- 1.27. (Annulled – State Gazette, issue 63 from 2016).
- 1.28. (Annulled – State Gazette, issue 63 from 2016).
- 1.29. (Annulled – State Gazette, issue 63 from 2016).

This is a translation from Bulgarian of the interim individual financial statements of "Sopharma" AD for the quarterly period ending on 30 September 2020.
In case of divergence Bulgarian text should prevail.

1.30. There is no opening or termination of a court or arbitration case relating to the debts or claims of the company or its subsidiary with a claim price of at least 10% of the company's equity.

1.31. Purchase, sale or established pledge of shares in commercial companies by the issuer or its subsidiary.

On March 19, 2020 "Sopharma Trading" AD announced the conclusion of a contract for the acquisition of the pharmacy Group "SCS Franchise". The merger of "Sopharmacy" and "SCS Franchise" will provide a stronger market position and an opportunity to further meet the growing needs of Bulgarian patients for quality healthcare services. The merger will also bring a nationwide expansion of "Sopharma Trading" AD's operations in the retail segment of the pharmacy market. The Commission for Protection of Competition is yet to pronounce on the deal.

By Decision № 626 / June 23, 2020, the Commission for Protection of Competition of the Republic of Bulgaria authorized the concentration within the meaning of Chapter V of the Law on Protection of Competition by acquiring sole control from "Sopharma Trading" AD over "SCS Franchise" AD and "Sanita Franchising" AD. Immediate execution of the decision was also ordered. The General Meeting of Shareholders of "Sopharma Trading" AD, which took place on September 25, 2020, authorizes the Board of Directors of the company to enter into a transaction within the scope of Art. 114, par. 1, it. 1 of LPOS under the terms and conditions, according to Section I of the Substantiated Report prepared by the Board of Directors.

On October 13, 2020 the company acquired an additional 5.01% of the capital of "Aromania" AD.

1.32. (Annulled – State Gazette, issue 63 from 2016).

1.33. (Annulled – State Gazette, issue 63 from 2016).

1.34. Other circumstances that the Company considers may be relevant to investors in taking a decision to acquire, sell or continue to hold publicly-traded securities: none.

"SOPHARMA" AD informs all interested parties that the interim financial statements of the Company as at September 30, 2020 have not been verified by a registered auditor.

/Signature/
Ognian Donev, PhD
/Executive Director/

***This is a translation from Bulgarian of the interim individual financial statements of "Sopharma" AD for the quarterly period ending on 30 September 2020.
In case of divergence Bulgarian text should prevail.***